Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...
Immuneering announces clinical supply agreement with Regeneron
Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...
Immuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus Libtayo
Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...
Students return: Part of Saint Rose campus to become workforce training center
The Center for Economic Growth will lead the project. The state will offer up to $300,000 for the center to develop a ...
Morningstar5d
Regeneron Pharmaceuticals Inc REGN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
pharmaphorum4d
Regeneron, Illumina join $320m Truveta investment
Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project. The two companies, along with 17 US health ...
pharmaphorum3d
After FDA no, Regeneron gets yes from EU on odronextamab
Regeneron's CD20xCD3 bispecific antibody for ... and 163,000 cases of DLBCL. "Building upon this approval, we are excited about our OLYMPIA program, which includes multiple phase 3 trials ...